drugset / Trial / NCT01498432

Physiological Response to Heliox21 and Air O2

NCT01498432 ↗

Phase 4 Unknown 38 enrolled University College, London
RandomizedCrossoverSingle-blindBasic science

Summary

This is a non-commercial study to explore the use of Heliox21 in a new patient cohort. The fundamental aim is to assess the therapeutic benefits of Heliox21 and practicalities of gas delivery in patients who require non-invasive ventilatory support following extubation on the Intensive Care Unit. Thus, the investigators aim to extend our knowledge of the potential role for Heliox21 in the post-extubation environment of the Intensive Care Unit. The purpose of this study is to answer a specific, clinically relevant question. That is whether Heliox21 helps to reduce the effort of breathing in the period following withdrawal of mechanically assisted ventilation in patients on the intensive care unit.

Timeline

Start
2012-01
Primary completion
2013-01
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Air O2 Unknown — —
Subject Heliox21 Unknown — Other

Indications